The UK approval of tirzepatide: what the evidence showed and what it means for you

What the trial data actually said when regulators reviewed tirzepatide

The MHRA's approval rested primarily on the SURMOUNT programme, a series of phase 3 trials in adults living with obesity or overweight. The headline result came from SURMOUNT-1, published in the New England Journal of Medicine: over 72 weeks, participants taking the 15mg dose lost around 20–21% of their body weight on average, compared with roughly 3% in the placebo group. Participants on lower doses also saw meaningful reductions. The trial enrolled 2,539 adults, describing it as involving thousands of participants is accurate; the programme across SURMOUNT and the earlier SURPASS diabetes series ran to over 10,000 participants in total.

What made these results stand out was the mechanism. If you want a fuller breakdown of how it works, our tirzepatide page covers the science behind the drug, including how it activates two gut-hormone receptors simultaneously, GIP and GLP-1, rather than the single GLP-1 pathway targeted by earlier medicines in the class. That dual action appears to produce a stronger appetite-suppressing effect than GLP-1 agonism alone. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, later confirmed that tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks, though both are effective medicines and the right choice for any person is always a clinical one.

The MHRA scrutinised safety data from the same programme before granting approval, which is why tirzepatide carries a Black Triangle (▼) designation, meaning it is subject to additional monitoring while real-world safety evidence accumulates. That is standard for newly approved medicines, not a signal of unusual concern.

MHRA approval versus NICE recommendation: two different decisions

A point that genuinely confuses people: NICE's appraisal of tirzepatide (TA1026), published in December 2024 and updated in September 2025, is not the same thing as the MHRA licence. The MHRA decides whether a medicine is safe and effective enough to be prescribed in the UK at all. NICE decides, separately, whether the NHS should fund it and for whom.

Under TA1026, NICE recommends tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related health condition, for example, high blood pressure, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, where the cut-off is reduced by 2.5 kg/m². If less than 5% weight loss is achieved after six months at the highest tolerated dose, the guidance says continuing should be reviewed.

The MHRA licence is broader: it covers adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition. That means many people who meet the private prescription criteria do not yet meet the NHS funding criteria. Neither set of criteria is a guarantee of approval for any individual, a prescriber assesses the full clinical picture before issuing a prescription.

If you want to understand the cost side of private treatment, the Mounjaro pricing page covers what private prescriptions typically include and what drives the variation between providers.

How the UK approval differs from the EMA process, and why it matters for patients

Since the UK left the EU, the MHRA operates its own licensing pathway independently of the European Medicines Agency. The tirzepatide EMA approval came separately, with the EMA authorising it for weight management in the EU in autumn 2023. The two decisions drew on overlapping evidence but were reached through distinct regulatory processes, and the MHRA's approval is the one that governs what can legally be prescribed and dispensed in the UK.

In practice this means that patients in the UK and patients in EU countries may encounter slightly different labelling, approved indications or monitoring requirements. For weight management, the core licence (adults with obesity, or overweight with a weight-related condition, alongside lifestyle changes) is consistent. But UK-specific guidance, including NICE's appraisal criteria and NHS England's phased rollout, applies only here. Pages comparing whether Mounjaro is approved in specific contexts are useful for navigating these distinctions.

One practical note: tirzepatide's approval date in the UK predates its availability on NHS formularies by over a year. MHRA approval in November 2023 opened the door for private prescriptions immediately; NHS access began phasing in only from June 2025 under TA1026's implementation schedule. That gap explains why many people came to private providers first, and why, even now that NHS access exists for some cohorts, waiting lists and eligibility criteria mean private treatment remains the realistic route for many. If you are unsure where you fall, our page on whether Mounjaro is approved for weight loss covers the eligibility picture in more detail.

What tirzepatide approval means if you are considering treatment now

The regulatory decisions described above have direct consequences for anyone thinking about starting treatment. Tirzepatide is a prescription-only medicine, and if you want a clear account of how tirzepatide gained approval for weight loss, that status flows directly from the MHRA licence and the evidence the regulator reviewed. It cannot legally be sold or supplied without a valid prescription issued following a clinical assessment. The NHS medicines page for tirzepatide is a reliable reference for understanding the medicine's profile, how it is taken, and what to discuss with a prescriber.

Treatment begins at a 2.5mg dose, which is a tolerability step: its job is to let your system adjust before the dose increases, not to produce the main therapeutic effect. Titration follows a schedule agreed with your prescriber, typically in four-weekly steps, up to a maximum of 15mg. Missed doses, timing changes and pace of titration are questions for the prescribing team and the patient information leaflet, not something to navigate alone.

A note on timing that comes up regularly: orders placed on a Monday, or just before a bank holiday, sometimes prompt questions about dispatch and delivery. At nume, orders placed before 12pm Monday to Friday are dispatched the same day once clinically approved, and delivered free the next working day by DPD. Delivery windows around public holidays are worth factoring in when planning your supply. Our clinical team reviews every consultation personally (the same day) and aftercare support runs seven days a week if questions come up after your treatment arrives.

Questions about who qualifies are also common at this stage, and our page on Mounjaro age approval sets out the age-related criteria that prescribers apply when assessing suitability. If you have read enough to want to find out whether you are eligible, a free consultation is the next step. Our prescribers will review your answers the same day and, if tirzepatide is clinically suitable, your prescription and treatment can follow without delay. Start your free consultation to get the process underway.